Avanir Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Avanir Pharmaceuticals, Inc.
New fund will include some later-stage investments in portfolio companies, in recognition of the currently tough environment for privately held biotechs.
The start-up is built around four business units – technology, manufacturing, R&D and therapeutics – based on internal and external expertise. Kriya will take its first gene therapies into the clinic in 2023.
US FDA closed out the month of April with two new molecular entity approvals that address underserved markets but carry some safety concerns.
Bristol already is training cardiologists at major treatment centers in how to treat obstructive hypertrophic cardiomyopathy with Camzyos (mavacamten) based on the REMS in the US label.
- Other Names / Subsidiaries
- Alamo Pharmaceuticals, LLC